Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.71 |
| ▸ | NPC1 | O15118 | 7/20 | 0.64 |
| ▸ | RAB9A | P51151 | 7/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.62 |
| ▸ | GSK3B | P49841 | 3/20 | 0.62 |
| ▸ | CSNK1G2 | P78368 | 3/20 | 0.62 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 4/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | PKM | P14618 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.58 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.58 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.57 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL239690 | 0.86 | MEN1 (0.75) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL30020996 | 0.86 | MEN1 (0.75) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL14881698 | 0.83 | MEN1 (0.71) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL20685416 | 0.83 | MEN1 (1.00) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6037541 | 0.83 | MEN1 (0.71) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1163897 | 0.83 | MEN1 (0.71) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1996591 | 0.83 | MEN1 (0.71) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL18236256 | 0.83 | AKR1C3 (0.63) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL23763480 | 0.83 | MEN1 (0.66) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2001471 | 0.83 | MEN1 (0.70) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030018016-A1 | Cell adhesion inhibitors | BIOGEN IDEC MA, INC. | 2003-01-23 | — | — | US | claimed |
| EP-0805796-B1 | CELL ADHESION INHIBITORS | BIOGEN INC (US) | 2002-12-11 | — | — | EP | claimed |
| EP-0805796-A1 | CELL ADHESION INHIBITORS | BIOGEN, INC. (US) | 1997-11-12 | — | — | EP | claimed |
| WO-1996022966-A1 | CELL ADHESION INHIBITORS | BIOGEN, INC. (US) | 1996-08-01 | — | — | WO | claimed |
| EP-3105210-B1 | BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS | Bayer Pharma AG (DE) | 2019-01-30 | — | — | EP | disclosed |
| US-7939551-B2 | for diabetes mellitus and other metabolic disorders; compounds of given formula such as sulfonamides and an antidiabetic agent such as sulfonylureas, biguanides, glitazones, alpha-glucosidase inhibitors, glucagon antagonists | AMGEN INC. (US) | 2011-05-10 | — | — | US | disclosed |
| US-7915255-B2 | Metabolism-modulating agents and uses therefor | VERVA PHARMACEUTICALS PTY LTD (AU) | 2011-03-29 | — | — | US | disclosed |
| US-20060166866-A1 | Cell adhesion inhibitors | BIOGEN, INC., A MASSACHUSETTS CORPORATION | 2006-07-27 | — | — | US | disclosed |
| US-6630512-B2 | Antiinflammatory agents; autoimmune disease | BIOGEN, INC. | 2003-10-07 | — | — | US | disclosed |
| US-20030018016-A1 | Cell adhesion inhibitors | BIOGEN IDEC MA, INC. | 2003-01-23 | — | — | US | disclosed |
| EP-0805796-B1 | CELL ADHESION INHIBITORS | BIOGEN INC (US) | 2002-12-11 | — | — | EP | disclosed |
| US-6376538-B1 | ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASES | BIOGEN, INC. | 2002-04-23 | — | — | US | disclosed |
| EP-1142867-A2 | Cell adhesion inhibitors | BIOGEN, INC. (US) | 2001-10-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166866-A1 | Cell adhesion inhibitors | ICAM1, VCAM1, EPCAM | MEN1 1437/4885KMT2A 3376/4885NPC1 2649/4885 |
| US-20030018016-A1 | Cell adhesion inhibitors | ICAM1, VCAM1, EPCAM | MEN1 1437/4885KMT2A 3376/4885NPC1 2649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.